ClinicalTrials.gg
CompletedNCT01474382Updated Aug 29, 2014

Study of OraVerse® for Safety and Efficacy in Pediatric Dental Patients

A Phase 4 interventional study of OraVerse and Sham injection in Dental Anesthesia, Anesthesia, Local and Anesthesia, Reversal, sponsored by Novocol Pharmaceutical of Canada, Inc.. Completed at 7 sites in United States. Open to participants aged 2 Years to 5 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-08-29.

Sponsored by Novocol Pharmaceutical of Canada, Inc. · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
2 Years to 5 Years
Sex
All
01

Study summary

The purpose of this study is to determine whether OraVerse is safe and effective for the reversal of dental anesthesia in children 2 to 5 years of age weighing at least 10 kg.

Read the detailed description

This Phase 4 clinical study is designed as a multicenter, randomized, double-blinded, controlled study to evaluate the safety and efficacy of OraVerse in approximately 150 children 2 to 5 years of age. OraVerse or sham injection is administered at the completion of a dental procedure requiring local anesthesia with lidocaine 2% with 1:100,000 epinephrine. The dental procedure(s) comprising restoration/fillings shall be performed in a single quadrant of the mouth.

The primary endpoint is safety and tolerability of OraVerse as measured by adverse events, vital signs, oral cavity assessments, nerve injury, and analgesics for intraoral pain. Secondary objectives in subjects 4 and 5 years of age include the safety and tolerability of OraVerse as measured by pain assessments using W-B PRS and evaluation of efficacy assessed by a pediatric Functional Assessment Battery (pFAB) and standardized lip and tongue palpation procedure.

02

Conditions studied

  • Dental Anesthesia
  • Anesthesia, Local
  • Anesthesia, Reversal

Keywords

  • OraVerse
  • Safety
  • Efficacy
  • Pediatric
  • Reversal of dental anesthesia
03

In context

Lead sponsor

This is the only study on the registry with Novocol Pharmaceutical of Canada, Inc. as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Years to 5 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, 2 to 5 years of age
  • Sufficiently healthy as determined by the Investigator to receive routine dental care
  • Requires a restorative procedure (restoration/filling) in a single quadrant of the mouth
  • Requires local anesthesia with lidocaine 2% with 1:100,000 epinephrine administered by submucosal injection
  • For subjects undergoing mandibular procedures, require an inferior alveolar nerve block for the restorative procedure
  • Dental procedure(s) completed within 60 minutes of injection of local anesthetic
  • For subjects 4 and 5 years of age, can be trained in standardized lip/tongue palpation procedure and pFAB
  • Subjects who are trainable in pFAB and standardized lip/tongue palpation procedure have either:

    • normal pFAB at baseline prior to administration of local anesthetic and
    • at least one abnormal function (smiling, speaking, drinking or drooling) at the completion of the dental procedure OR
    • normal lip sensation at baseline prior to administration of local anesthetic and
    • numbness of the relevant lip quadrant at completion of the dental procedure
  • Subjects give written or verbal assent, as capable and appropriate, and parent(s) or legal guardian(s) give written

Exclusion criteria

Exclusion Criteria:

  • Weight less than 10 kg
  • Weight less than 15 kg if 4 or 5 years of age
  • History or presence of any condition that contraindicates routine dental care or use of local anesthetic
  • Requires more than ¼ cartridge of local anesthetic if weight is ≥ 10 kg and \< 15 kg, more than ½ cartridge of local anesthetic if weight is ≥ 15 kg and \< 30 kg, and more than 1 cartridge of local anesthetic if weight is ≥ 30 kg, excluding supplemental injections
  • Allergy or intolerance to lidocaine, epinephrine, sulfites, phentolamine, nitrous oxide or topical benzocaine
  • Has used any drug and/or participated in any clinical study within 30 days of study drug administration
  • Has participated in this study or any previous study of phentolamine mesylate for reversal of local soft tissue anesthesia (STA)
  • Any use of commercial OraVerse™ within 30 days of study drug administration
  • Use of opioid or opioid-like analgesics within 24 hours prior to administration of local anesthetic
  • Requires the use of local anesthetic other than lidocaine 2% with 1:100,000 epinephrine to perform the scheduled dental procedure
  • Requires the use of general anesthesia or sedatives except for nitrous oxide to perform the scheduled dental procedure
  • Any condition which in the opinion of the Investigator increases the risk to the subject of participating in this study or decreases the likelihood of compliance with the protocol
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
150 participants (actual)

Study arms

  • Experimental
    OraVerse

    OraVerse in doses of either 1/4, 1/2 or 1 cartridge (1.8mL)

    Drug: OraVerse

  • Sham comparator
    Sham injection

    Dentist simulates injection with dental syringe

    Other: Sham injection

Interventions

  • 1.8mL dental cartridge delivered in doses of either 1/4, 1/2 or 1 cartridge depending on subject weight

  • OtherSham injection

    No drug administered, simulation of injection used in same manner as drug

06

What researchers measure

Primary outcomes

  1. Incidence and severity of adverse events

    Time frame: Up to 3 days

  2. Clinically significant changes in vital signs

    Blood pressure and pulse

    Time frame: Up to 3 days

  3. Clinically significant changes in oral cavity assessments

    Time frame: Up to 3 days

  4. Nerve injury

    Time frame: Up to 3 days

  5. Analgesics required for intraoral pain

    Time frame: Up to 3 days

Secondary outcomes

  1. incidence, severity and duration of intraoral pain as measured by W-B PRS

    Wong-Baker Pain Rating Scale used to assess subject pain

    Time frame: Up to 3 days

  2. Time to normal function

    Measured by pediatric Functional Assessment Battery (pFAB) to determine when speaking, eating, drinking, drooling return to baseline

    Time frame: Up to 3 days

  3. Time to normal lip sensation

    Measures time to normal lip and tongue sensation using standardized lip/tongue palpation procedure

    Time frame: Up to 3 days

  4. Time to normal tongue sensation

    Measures time to normal tongue sensation using standardized lip/tongue palpation procedure

    Time frame: Up to 3 days

07

Study locations

7 sites
  • University of California, San Francisco
    San Francisco, California 94143, United States
  • Indiana University School of Dentistry
    Indianapolis, Indiana 46202, United States
  • Nationwide Children's Hospital
    Columbus, Ohio 43205, United States
  • University of Pennsylvania School of Dental
    Philadelphia, Pennsylvania 19104-6030, United States
  • University of Pittsburgh School of Dental Medicine
    Pittsburgh, Pennsylvania 15261, United States
  • Jean Brown Research
    Salt Lake City, Utah 84124, United States
  • Center for Pediatric Dentistry
    Seattle', Washington 98115, United States
08

References and documents

Publications

  • Hersh EV, Moore PA, Papas AS, Goodson JM, Navalta LA, Rogy S, Rutherford B, Yagiela JA; Soft Tissue Anesthesia Recovery Group. Reversal of soft-tissue local anesthesia with phentolamine mesylate in adolescents and adults. J Am Dent Assoc. 2008 Aug;139(8):1080-93. doi: 10.14219/jada.archive.2008.0311. PubMed 18682623 ↗
  • Moore PA, Hersh EV, Papas AS, Goodson JM, Yagiela JA, Rutherford B, Rogy S, Navalta L. Pharmacokinetics of lidocaine with epinephrine following local anesthesia reversal with phentolamine mesylate. Anesth Prog. 2008 Summer;55(2):40-8. doi: 10.2344/0003-3006(2008)55[40:POLWEF]2.0.CO;2. PubMed 18547152 ↗
  • Tavares M, Goodson JM, Studen-Pavlovich D, Yagiela JA, Navalta LA, Rogy S, Rutherford B, Gordon S, Papas AS; Soft Tissue Anesthesia Reversal Group. Reversal of soft-tissue local anesthesia with phentolamine mesylate in pediatric patients. J Am Dent Assoc. 2008 Aug;139(8):1095-104. doi: 10.14219/jada.archive.2008.0312. Erratum In: J Am Dent Assoc. 2008 Oct;139(10):1312. PubMed 18682624 ↗
  • Laviola M, McGavin SK, Freer GA, Plancich G, Woodbury SC, Marinkovich S, Morrison R, Reader A, Rutherford RB, Yagiela JA. Randomized study of phentolamine mesylate for reversal of local anesthesia. J Dent Res. 2008 Jul;87(7):635-9. doi: 10.1177/154405910808700717. PubMed 18573982 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2012, a primary completion of Aug 2014 and a completion of Aug 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2011
First posted
Nov 18, 2011
Start
Feb 2012
Primary completionActual
Aug 2014
CompletionActual
Aug 2014
Last update
Aug 29, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 29, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01474382
Lead sponsor
Novocol Pharmaceutical of Canada, Inc.
Responsible party
Sponsor
First posted
Nov 18, 2011
Start date
Feb 2012
Primary completion
Aug 2014
Completion
Aug 2014
Last update
Aug 29, 2014

Study contacts

Paul Moore, DMD,PhD,MPH
principal investigator · University of Pittsburgh School of Dental Medicine
Elliot Hersh, DMD,MS,PhD
principal investigator · University of Pennsylvania
Joel Berg, DDS,MS
principal investigator · Seattle Children's Hospital
Judith Chin, DDS,MS
principal investigator · Indiana University
Brent Lin, DMD
principal investigator · University of California, San Francisco
Paul Casamassimo, MS,DDS
principal investigator · Nationwide Children's Hospital
Adam Marberger, DDS
principal investigator · Jean Brown Research

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Phentolamine

Start the discussion